Share on facebook Share on Twitter Share on Google Plus Share This
Back to Results


Title A randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in patients with Advanced Classical Hodgkin Lymphoma
Therapeutic Area Lymphomas (adult), Hodgkin Lymphoma
Principal Investigator Andreas Klein, MD
Min Age 18 Years
Gender Both
Contact Liz Kendricken, RN


The purpose of this study is to find out what effects, good and/or bad, the addition of lenalidomide to standard chemotherapy (RCHOP) has on you and your cancer. Everybody in this study will receive standard chemotherapy.  In addition to standard chemotherapy randomly chosen half of the subjects will receive a medication called lenalidomide.  Adding lenalidomide to the standard chemotherapy RCHOP is considered experimental in diffuse large B cell lymphoma, and is not FDA approved. There is NO placebo (“sugar pill”) in this study, and everybody selected will receive an active medication.

Study Details

Inclusion Criteria

  • Adequate organ function
  • Newly diagnosed with stage III or IV classical Hodgkin Lymphoma and have not received treatments

Exclusion Criteria

  • Any sensory or motor peripheral neuropathy
  • Known human immunodeficiency virus (HIV) positive

Study Requirements

Participants will receive the following study regimen with or without lenalidomide depending on randomization:  Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone. Participants will have physical exams, blood draws, PET/CT scans, and other procedures as per protocol. There will be about 10 visits during outpatient investigation drug regime and 2-3 year follow up and the end of study.
Nurse navigators for cancer patients at Tufts Medical Center.

Are you interested in learning more about this clinical trial?

Send us a message and we'll get back to you with more information.

Request information